JPWO2022150516A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022150516A5 JPWO2022150516A5 JP2023540918A JP2023540918A JPWO2022150516A5 JP WO2022150516 A5 JPWO2022150516 A5 JP WO2022150516A5 JP 2023540918 A JP2023540918 A JP 2023540918A JP 2023540918 A JP2023540918 A JP 2023540918A JP WO2022150516 A5 JPWO2022150516 A5 JP WO2022150516A5
- Authority
- JP
- Japan
- Prior art keywords
- wild
- residue
- type human
- position corresponding
- human neu2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134411P | 2021-01-06 | 2021-01-06 | |
| US63/134,411 | 2021-01-06 | ||
| US202163217998P | 2021-07-02 | 2021-07-02 | |
| US63/217,998 | 2021-07-02 | ||
| PCT/US2022/011499 WO2022150516A1 (en) | 2021-01-06 | 2022-01-06 | Sialidase-her2-antibody fusion proteins and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501767A JP2024501767A (ja) | 2024-01-15 |
| JP2024501767A5 JP2024501767A5 (https=) | 2025-01-23 |
| JPWO2022150516A5 true JPWO2022150516A5 (https=) | 2025-01-23 |
Family
ID=82357542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540918A Withdrawn JP2024501767A (ja) | 2021-01-06 | 2022-01-06 | シアリダーゼ－ｈｅｒ２－抗体融合タンパク質、及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240059792A1 (https=) |
| EP (1) | EP4274892A4 (https=) |
| JP (1) | JP2024501767A (https=) |
| KR (1) | KR20230138473A (https=) |
| AU (1) | AU2022206263A1 (https=) |
| CA (1) | CA3173668A1 (https=) |
| IL (1) | IL304233A (https=) |
| MX (1) | MX2023008027A (https=) |
| WO (1) | WO2022150516A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022006492A2 (en) * | 2020-07-03 | 2022-01-06 | Palleon Pharmaceuticals Inc. | Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same |
| WO2026037175A1 (zh) | 2024-08-16 | 2026-02-19 | 上海宝济药业股份有限公司 | 靶向靶细胞的复合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10081801B2 (en) * | 2013-04-12 | 2018-09-25 | Danmarks Tekniske Universitet | Mutant sialidase having trans-sialidase activity for use in production of sialylated glycans |
| KR102914621B1 (ko) * | 2018-01-03 | 2026-01-21 | 팔레온 파마슈티칼스 인크. | 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법 |
| WO2020142727A1 (en) * | 2019-01-03 | 2020-07-09 | Palleon Pharmaceuticals Inc. | Methods and compositions for treating cancer with immune cells |
| WO2020172072A1 (en) * | 2019-02-21 | 2020-08-27 | The General Hospital Corporation | Glycoengineering immunoglobulin e |
| CA3135531A1 (en) * | 2019-04-30 | 2020-11-05 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| WO2022006492A2 (en) * | 2020-07-03 | 2022-01-06 | Palleon Pharmaceuticals Inc. | Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same |
| US20240067729A1 (en) * | 2021-01-06 | 2024-02-29 | Palleon Pharmaceuticals Inc. | Anti-pd-l1 antibodies and fusion proteins thereof |
-
2022
- 2022-01-06 WO PCT/US2022/011499 patent/WO2022150516A1/en not_active Ceased
- 2022-01-06 JP JP2023540918A patent/JP2024501767A/ja not_active Withdrawn
- 2022-01-06 EP EP22737130.9A patent/EP4274892A4/en not_active Withdrawn
- 2022-01-06 US US18/260,383 patent/US20240059792A1/en active Pending
- 2022-01-06 MX MX2023008027A patent/MX2023008027A/es unknown
- 2022-01-06 AU AU2022206263A patent/AU2022206263A1/en not_active Abandoned
- 2022-01-06 KR KR1020237026706A patent/KR20230138473A/ko not_active Withdrawn
- 2022-01-06 CA CA3173668A patent/CA3173668A1/en active Pending
-
2023
- 2023-07-04 IL IL304233A patent/IL304233A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11905322B2 (en) | Engineered PD-1 variants | |
| CA2222757C (en) | Modified/chimeric superantigens and their use | |
| US20220281936A1 (en) | Compositions and methods comprising protease-activated therapeutic agents | |
| JP2023123649A5 (https=) | ||
| JP2020530296A5 (https=) | ||
| JP2021505156A5 (https=) | ||
| JP2009517006A5 (https=) | ||
| WO2023186120A1 (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| CN115916809A (zh) | 人il-15突变体及其用途 | |
| JPWO2021189139A5 (https=) | ||
| CN113631582A (zh) | 一种融合蛋白及其用途 | |
| CN104292331B (zh) | 人源抗人α干扰素抗体及其应用 | |
| JP2025512119A (ja) | 抗ｐｄ－１モノクローナル抗体、その誘導体及びその使用 | |
| JPWO2019121906A5 (ja) | Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片 | |
| JPWO2021116182A5 (https=) | ||
| WO2022011110A2 (en) | Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection | |
| KR20250028265A (ko) | 항체 및 이의 용도 | |
| JPWO2022150516A5 (https=) | ||
| JPWO2021003469A5 (https=) | ||
| CN118284699A (zh) | 包含SIRPα突变体的融合蛋白 | |
| JPWO2022006492A5 (https=) | ||
| JP2023550191A (ja) | Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法 | |
| JPWO2020197400A5 (https=) | ||
| WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
| JPWO2022150521A5 (https=) |